SCHEMBL7710882

SCHEMBL7710882

COc1cccc(-c2ccc3c(c2)C(/N=C(/N)N(C)C=O)c2ccncc2O3)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCNC P24863 2/20 0.38
CDK8 P49336 2/20 0.38
HASPIN Q8TF76 2/20 0.38
JAK2 O60674 1/20 0.36
NPC1 O15118 2/20 0.36
RAB9A P51151 2/20 0.36
HPGD P15428 1/20 0.36
RPS6KA3 P51812 1/20 0.35
CYP11B1 P15538 1/20 0.35
CYP11B2 P19099 1/20 0.35
DAPK3 O43293 1/20 0.35
CDC7 O00311 1/20 0.34
CHEK2 O96017 1/20 0.34
PLAU P00749 1/20 0.34
HSD17B1 P14061 1/20 0.34
SLC22A12 Q96S37 1/20 0.33
MGAT2 Q10469 1/20 0.33
GPR142 Q7Z601 1/20 0.33
CYP1A2 P05177 3/20 0.33
CYP3A4 P08684 3/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7712995 0.84 BACE1 (0.41) CYP11B1CYP11B2CYP1A2CYP3A4CTSD
SCHEMBL7715200 0.83 MKNK1 (0.37) CYP11B1CYP11B2CYP1A2CYP3A4CYP2D6
SCHEMBL7710836 0.81 ERN1 (0.35) NPC1RAB9AHPGDHSD17B1CYP1A2
SCHEMBL7711100 0.79 KDR (0.39) CYP11B1CYP11B2MAPT
SCHEMBL7708344 0.79 ERN1 (0.32) BACE1
SCHEMBL7705409 0.79 BACE1 (0.45) CTSDBACE1DHODH
SCHEMBL7710613 0.78 CYP11B1 (0.38) CYP11B1CYP11B2CYP1A2CYP3A4CYP2D6
SCHEMBL7711197 0.76 MKNK1 (0.37) CYP11B1CYP11B2CYP1A2CYP3A4CYP2C19
SCHEMBL7712670 0.73 ERN1 (0.34) CYP11B2BACE1
SCHEMBL7705408 0.70 BACE1 (0.35) CTSDBACE1DHODH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2011130741-A1 COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES ARRAY BIOPHARMA INC. (US) 2011-10-20 WO disclosed